Summary
A double blind, cross-over design was used to compare the acute effects of timegadine, naproxen and placebo in rheumatoid arthritis. Timegadine appeared to be more effective than naproxen in those variables related to disease activity although there were no statistically significant differences (apart from morning stiffness) where variables were examined individually. There was a tendency to a rise in alkaline phosphatase, and possibly gamma glutamyl transpeptidase, during the 2-week timegadine treatment period. No other biochemical or haematological abonormality was observed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rachlin, S., Bramm, E., Arnfelt-Rønne, I., Arrigoni-Martelli, E. Basic anti-inflammatory compounds: N, N′, N″ — trisubstituted guandines. J Med Chem, 1980, 23, 13–20.
Bramm, E., Binderup, L., Arrigoni-Martelli, E. An unusual profile of activity of a new basic antiinflammatory drug timegadine. Agents Actions, 1981, 11, 402–409.
Ahnfelt-Rønne, I., Arrigoni-Martelli, E. A new antiinflammatory compound, timegadine (N-cyclohex-lN″-4 — (2-methylquinolyl)-N′-2-thiazolylguanidine), which inhibits both prostaglandin and 12-hydroxyeicosatetraenoic acid (12-HETE) formulation. Biochem Pharmacol, 1980, 29, 3265–3269.
Ritchie, D.M., Boyle, J.A., McInnes, J.M. et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med, 1968, 37, 393–406.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Berry, H., Bloom, B., Fernandes, L. et al. Comparison of timegadine and naproxen in rheumatoid arthritis. A placebo controlled trial. Clin Rheumatol 2, 357–361 (1983). https://doi.org/10.1007/BF02041555
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02041555